Valerie Leung1, Michael Li2, Julie Hui-Chih Wu1, Bradley Langford1, Rosemary Zvonar3, Jeff Powis4, Julie Longpre5, Lizanne Béïque3, Suzanne Gill6, Grace Ho6, Gary Garber7,8,9. 1. Infection Prevention and Control, Public Health Ontario. 2. Leslie Dan Faculty of Pharmacy, University of Toronto. 3. Department of Pharmacy, The Ottawa Hospital and Ottawa Hospital Research Institute. 4. Department of Medicine, Michael Garron Hospital, Toronto. 5. Department of Pharmacy, Cornwall Community Hospital. 6. Department of Pharmaceutial Services, Michael Garron Hospital, Toronto. 7. Division of Infectious Diseases, The Ottawa Hospital. 8. Department of Medicine, University of Toronto, Toronto, Canada. 9. Department of Medicine, University of Ottawa, Canada.
Abstract
BACKGROUND: Antimicrobial stewardship, a key component of an overall strategy to address antimicrobial resistance, has been recognized as a global priority. The ability to track and benchmark antimicrobial use (AMU) is critical to advancing stewardship from an organizational and provincial perspective. As there are few comprehensive systems in Canada that allow for benchmarking, Public Health Ontario conducted a pilot in 2016/2017 to assess the feasibility of using a point prevalence methodology as the basis of a province-wide AMU surveillance program. METHODS: Three acute care hospitals of differing sizes in Ontario, Canada, participated. Adults admitted to inpatient acute care beds on the survey date were eligible for inclusion; a sample size of 170 per hospital was targeted, and data were collected for the 24-hour period before and including the survey date. Debrief sessions at each site were used to gather feedback about the process. Prevalence of AMU and the Antimicrobial Spectrum Index (ASI) was reported for each hospital and by indication per patient case. RESULTS: Participants identified required improvements for scalability including streamlining ethics, data sharing processes, and enhancing the ability to compare with peer organizations at a provincial level. Of 457 patients, 172 (38%) were receiving at least 1 antimicrobial agent. Beta-lactam/beta-lactamase inhibitors were the most common (18%). The overall mean ASI per patient was 6.59; most cases were for treatment of infection (84%). CONCLUSIONS: This pilot identified factors and features required for a scalable provincial AMU surveillance program; future efforts should harmonize administrative processes and enable interfacility benchmarking.
BACKGROUND: Antimicrobial stewardship, a key component of an overall strategy to address antimicrobial resistance, has been recognized as a global priority. The ability to track and benchmark antimicrobial use (AMU) is critical to advancing stewardship from an organizational and provincial perspective. As there are few comprehensive systems in Canada that allow for benchmarking, Public Health Ontario conducted a pilot in 2016/2017 to assess the feasibility of using a point prevalence methodology as the basis of a province-wide AMU surveillance program. METHODS: Three acute care hospitals of differing sizes in Ontario, Canada, participated. Adults admitted to inpatient acute care beds on the survey date were eligible for inclusion; a sample size of 170 per hospital was targeted, and data were collected for the 24-hour period before and including the survey date. Debrief sessions at each site were used to gather feedback about the process. Prevalence of AMU and the Antimicrobial Spectrum Index (ASI) was reported for each hospital and by indication per patient case. RESULTS: Participants identified required improvements for scalability including streamlining ethics, data sharing processes, and enhancing the ability to compare with peer organizations at a provincial level. Of 457 patients, 172 (38%) were receiving at least 1 antimicrobial agent. Beta-lactam/beta-lactamase inhibitors were the most common (18%). The overall mean ASI per patient was 6.59; most cases were for treatment of infection (84%). CONCLUSIONS: This pilot identified factors and features required for a scalable provincial AMU surveillance program; future efforts should harmonize administrative processes and enable interfacility benchmarking.
Authors: Mamoon A Aldeyab; Mary P Kearney; James C McElnay; Fidelma A Magee; Geraldine Conlon; Dianne Gill; Peter Davey; Arno Muller; Herman Goossens; Michael G Scott Journal: Br J Clin Pharmacol Date: 2011-02 Impact factor: 4.335
Authors: Jeffrey S Gerber; Adam L Hersh; Matthew P Kronman; Jason G Newland; Rachael K Ross; Talene A Metjian Journal: Infect Control Hosp Epidemiol Date: 2017-05-31 Impact factor: 3.254
Authors: Joshua Osowicki; Amanda Gwee; Jesuina Noronha; Pamela Palasanthiran; Brendan McMullan; Philip N Britton; David Isaacs; Tony Lai; Clare Nourse; Minyon Avent; Paul Moriarty; Julia Clark; Joshua R Francis; Christopher C Blyth; Celia M Cooper; Penelope A Bryant Journal: Med J Aust Date: 2014-12-11 Impact factor: 7.738
Authors: P Zarb; B Coignard; J Griskeviciene; A Muller; V Vankerckhoven; K Weist; Mm Goossens; S Vaerenberg; S Hopkins; B Catry; Dl Monnet; H Goossens; C Suetens Journal: Euro Surveill Date: 2012-11-15
Authors: Geoffrey Taylor; Denise Gravel; Lynora Saxinger; Kathryn Bush; Kimberley Simmonds; Anne Matlow; Joanne Embree; Nicole Le Saux; Lynn Johnston; Kathryn N Suh; John Embil; Elizabeth Henderson; Michael John; Virginia Roth; Alice Wong Journal: Can J Infect Dis Med Microbiol Date: 2015 Mar-Apr Impact factor: 2.471
Authors: Colin Lee; Sandra A N Walker; Nick Daneman; Marion Elligsen; Lesley Palmay; Bryan Coburn; Andrew Simor Journal: J Epidemiol Glob Health Date: 2014-08-08
Authors: Maria Diletta Pezzani; Elena Carrara; Marcella Sibani; Elisabeth Presterl; Petra Gastmeier; Hanna Renk; Souha S Kanj; Thirumalaisamy P Velavan; Le Huu Song; Leonard Leibovici; Didem Torumkuney; Tomislav Kostyanev; Marc Mendelson; Evelina Tacconelli Journal: J Antimicrob Chemother Date: 2020-12-06 Impact factor: 5.790
Authors: Annemieke K van den Broek; Berend H H Beishuizen; Eric A F Haak; Michiel Duyvendak; Jaap Ten Oever; Chris Sytsma; Mieke van Triest; Cornelia C H Wielders; Jan M Prins Journal: Antimicrob Resist Infect Control Date: 2021-07-03 Impact factor: 4.887